Nautilus Biotechnology, Inc. Research and Development Expense
Nautilus Biotechnology, Inc. (NAUT) reported Research and Development Expense of $9.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-28
- Nautilus Biotechnology, Inc. research and development expense for the quarter ending 2026-06-30 was $9.61M, a 7.51% decline year-over-year.
- Nautilus Biotechnology, Inc. research and development expense for the quarter ending 2026-03-31 was $9.71M, a 15.85% decline year-over-year.
- Nautilus Biotechnology, Inc. research and development expense for the quarter ending 2025-12-31 was $9.57M, a 25.33% decline year-over-year.
- Nautilus Biotechnology, Inc. research and development expense for the quarter ending 2025-09-30 was $9.61M, a 21.83% decline year-over-year.
- Nautilus Biotechnology, Inc. research and development expense for fiscal 2025 was $41.11M, a 18.56% decline from fiscal 2024.
- Nautilus Biotechnology, Inc. research and development expense for fiscal 2024 was $50.48M, a 6.83% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. research and development expense for fiscal 2023 was $47.25M, a 25.43% increase from fiscal 2022.
- Nautilus Biotechnology, Inc. research and development expense for fiscal 2022 was $37.67M, a 28.35% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.61M 10-Q · filed 2026-07-28 | $19.32M 10-Q · filed 2026-07-28 | $28.89M derived: sum of 3 quarters · filed 2026-07-28 | $38.50M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $9.71M 10-Q · filed 2026-04-28 | $19.28M derived: sum of 2 quarters · filed 2026-04-28 | $28.89M derived: sum of 3 quarters · filed 2026-04-28 | $39.28M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $9.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.18M derived: sum of 2 quarters · filed 2026-02-26 | $29.57M derived: sum of 3 quarters · filed 2026-07-28 | $41.11M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.61M 10-Q · filed 2025-10-28 | $20.00M derived: sum of 2 quarters · filed 2026-07-28 | $31.54M 10-Q · filed 2025-10-28 | $44.36M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $10.39M 10-Q · filed 2026-07-28 | $21.93M 10-Q · filed 2026-07-28 | $34.75M derived: sum of 3 quarters · filed 2026-07-28 | $47.04M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $11.54M 10-Q · filed 2026-04-28 | $24.36M derived: sum of 2 quarters · filed 2026-04-28 | $36.65M derived: sum of 3 quarters · filed 2026-04-28 | $49.08M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $12.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.11M derived: sum of 2 quarters · filed 2026-02-26 | $37.55M derived: sum of 3 quarters · filed 2026-02-26 | $50.48M 10-K · filed 2026-02-26 |
| 2024-09-30 | $12.29M 10-Q · filed 2025-10-28 | $24.72M derived: sum of 2 quarters · filed 2025-10-28 | $37.65M 10-Q · filed 2025-10-28 | $50.12M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-06-30 | $12.44M 10-Q · filed 2025-07-31 | $25.37M 10-Q · filed 2025-07-31 | $37.83M derived: sum of 3 quarters · filed 2025-07-31 | $49.83M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $12.93M 10-Q · filed 2025-04-29 | $25.40M derived: sum of 2 quarters · filed 2025-04-29 | $37.39M derived: sum of 3 quarters · filed 2025-04-29 | $49.30M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | $12.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $24.46M derived: sum of 2 quarters · filed 2025-02-27 | $36.37M derived: sum of 3 quarters · filed 2025-02-27 | $47.25M 10-K · filed 2025-02-27 |
| 2023-09-30 | $12.00M 10-Q · filed 2024-10-29 | $23.91M derived: sum of 2 quarters · filed 2024-10-29 | $34.78M 10-Q · filed 2024-10-29 | $44.37M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $11.91M 10-Q · filed 2024-07-30 | $22.79M 10-Q · filed 2024-07-30 | $32.38M derived: sum of 3 quarters · filed 2024-07-30 | $41.95M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $10.88M 10-Q · filed 2024-04-30 | $20.46M derived: sum of 2 quarters · filed 2024-04-30 | $30.04M derived: sum of 3 quarters · filed 2024-04-30 | $38.89M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | $9.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $19.16M derived: sum of 2 quarters · filed 2024-02-28 | $28.01M derived: sum of 3 quarters · filed 2024-02-28 | $37.67M 10-K · filed 2024-02-28 |
| 2022-09-30 | $9.57M 10-Q · filed 2023-10-31 | $18.43M derived: sum of 2 quarters · filed 2023-10-31 | $28.09M 10-Q · filed 2023-10-31 | $37.98M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | $8.86M 10-Q · filed 2023-08-02 | $18.51M 10-Q · filed 2023-08-02 | $28.41M derived: sum of 3 quarters · filed 2023-08-02 | $36.65M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $9.66M 10-Q · filed 2023-05-02 | $19.55M derived: sum of 2 quarters · filed 2023-05-02 | $27.80M derived: sum of 3 quarters · filed 2023-05-02 | $34.17M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $18.14M derived: sum of 2 quarters · filed 2023-02-23 | $24.52M derived: sum of 3 quarters · filed 2023-02-23 | $29.35M 10-K · filed 2023-02-23 |
| 2021-09-30 | $8.24M 10-Q · filed 2022-11-01 | $14.62M derived: sum of 2 quarters · filed 2022-11-01 | $19.46M 10-Q · filed 2022-11-01 | $23.35M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $6.38M 10-Q · filed 2022-08-02 | $11.21M 10-Q · filed 2022-08-02 | $15.11M derived: sum of 3 quarters · filed 2022-08-02 | $18.43M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $4.83M 10-Q · filed 2022-05-03 | $8.73M derived: sum of 2 quarters · filed 2022-05-03 | $12.05M derived: sum of 3 quarters · filed 2022-05-03 | $14.80M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $7.21M derived: sum of 2 quarters · filed 2022-02-24 | $9.96M derived: sum of 3 quarters · filed 2022-02-24 | $12.43M 10-K · filed 2022-02-24 |
| 2020-09-30 | $3.32M 10-Q · filed 2021-11-02 | $6.07M derived: sum of 2 quarters · filed 2021-11-02 | $8.54M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $2.75M 10-Q · filed 2021-08-10 | $5.22M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |